Press release
Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June
Three Poster Presentations Granted to Discuss Oral Insulin Candidate ORMD-0801 NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq:
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"Three Poster Presentations Granted to Discuss Oral Insulin Candidate ORMD-0801\n\n\nNEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present during the 80th American Diabetes Association Scientific Sessions, held virtually this year June 12-16, 2020.\n\n \n \n \n \n \n \n\n \nOramed's Chief Scientific Officer, Dr. Miriam Kidron, commented, \"We are thrilled that the American Diabetes Association (ADA) granted us the opportunity to present three important posters regarding our oral insulin candidate, ORMD-0801. We look forward to sharing with ADA participants ORMD-0801's impact on type-2 diabetes mellitus (T2DM), with better diabetes control, as well as its impact on fatty liver in nonalcoholic steatohepatitis (NASH).\"\nOramed's poster presentations include:\nOral Insulin (ORMD-0801) Effects on Glucose Parameters in Uncontrolled T2DM on Oral Antibiotic Drugs (OADs) Oral Insulin–Induced Reduction in Liver Fat Content in T2DM Patients with Nonalcoholic Steatohepatitis (NASH) Evening Oral Insulin (ORMD-0801) Glycemic Effects in Uncontrolled T2DM PatientsPresenters and viewing options will be announced as this information becomes available, prior to the ADA sessions in June.\nAbout Oramed Pharmaceuticals\nOramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.\nFor more information, please visit www.oramed.com.\nForward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential of ORMD-0...